

Special Issue

Epigenetic Regulation in Hematologic Malignancies

Message from the Guest Editor

Announcing the call for submissions to a Special Issue of *Cancers* focused on "Epigenetic Regulation in Hematologic Malignancies." Epigenetic mechanisms play a crucial role in the development, progression, and treatment response of hematologic malignancies. This Special Issue aims to provide a comprehensive overview of current research and advancements in the field. We invite original research articles and reviews covering topics such as epigenetic alterations, interplay with the tumor microenvironment, non-coding RNAs, immune responses, and therapeutic targeting. Submitted articles will undergo rigorous peer review. We encourage contributions from researchers, clinicians, and experts in the field. By consolidating research findings, this Special Issue aims to deepen our understanding and facilitate the development of innovative therapeutic strategies. Contact us for more information or assistance. We eagerly await your valuable submissions.

Guest Editor

Dr. Travis S. Johnson
Indiana University School of Medicine, Indianapolis, IN, USA

Deadline for manuscript submissions

30 June 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/205307

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)